[1]
NV, V. et al. 2025. An Audit of Efficacy and Toxicity of Neoadjuvant Paclitaxel and Trastuzumab in HER- 2 Postive Locally Advanced Breast Cancer. Asian Pacific Journal of Cancer Care. 10, 2 (Apr. 2025), 387–391. DOI:https://doi.org/10.31557/apjcc.2025.10.2.387-391.